Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s41669-017-0050-3 http://scihub22266oqcxt.onion/10.1007/s41669-017-0050-3 C5972121!5972121!29623622     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacoecon+Open 2018 ; 2 (2): 209-19 Nephropedia Template TP {{tp|p=29623622|t=2018. Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis |pdf=|usr=}}{{29623622}} gab.com Text Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis JO: Pharmacoecon Open http://www.kidney.de/pget.php?&tw=1&pmid=29623622 #FOAvip Objectives: Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods: Data were drawn from a random sample of ?600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results: Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were ?6506 ± 10,106 in the T2DM group as compared with ?3668 ± 6954 in the control group. The cost difference between the two groups was ?2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (?4153 ± 6170) and highest for those receiving insulin (?12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion: Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over ?8.5 billion. This estimate highlights the substantial economic burden of this condition on society. Electronic supplementary material: The online version of this article (doi:10.1007/s41669-017-0050-3) contains supplementary material, which is available to authorized users. Twit Text FOAVip Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis ????Pharmacoecon Open http://www.kidney.de/pget.php?&tw=1&pmid=29623622 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29623622 #FOAvip English Wikipedia <ref>{{Cite pmid|29623622}}</ref> Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis #MMPMID29623622 Charbonnel B; Simon D; Dallongeville J; Bureau I; Dejager S; Levy-Bachelot L; Gourmelen J; Detournay B Pharmacoecon Open 2018[Jun]; 2 (2): 209-19 PMID29623622show ga Objectives: Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods: Data were drawn from a random sample of ?600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results: Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were ?6506 ± 10,106 in the T2DM group as compared with ?3668 ± 6954 in the control group. The cost difference between the two groups was ?2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (?4153 ± 6170) and highest for those receiving insulin (?12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion: Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over ?8.5 billion. This estimate highlights the substantial economic burden of this condition on society. Electronic supplementary material: The online version of this article (doi:10.1007/s41669-017-0050-3) contains supplementary material, which is available to authorized users. äDirect Medical Costs of Type 2 Diabetes in France: An Insurance Claims(epmc).pdf DeepDyve Pubget Overpricing